IRIX Stock Overview An ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. More details
Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
IRIDEX Corporation Competitors Price History & Performance
Summary of share price highs, lows and changes for IRIDEX Historical stock prices Current Share Price US$1.64 52 Week High US$3.65 52 Week Low US$1.27 Beta 0.82 1 Month Change -8.89% 3 Month Change -9.39% 1 Year Change -36.80% 3 Year Change -73.63% 5 Year Change -30.21% Change since IPO -84.00%
Recent News & Updates
Iridex Corporation Announces Publication of Peer-Reviewed Study in Ophthalmology Therapy Dec 19
Iridex Corporation Comments on Changing Glaucoma Reimbursement Landscape Nov 20
IRIDEX Corporation Announces Board and Committee Changes Nov 16
IRIDEX Corporation to Report Q3, 2024 Results on Nov 12, 2024 Nov 05 Iridex Corporation Announces Chief Executive Officer Changes IRIDEX Corporation announced that it expects to receive $5 million in funding from The Lind Partners, LLC Aug 06
See more updates
Iridex Corporation Announces Publication of Peer-Reviewed Study in Ophthalmology Therapy Dec 19
Iridex Corporation Comments on Changing Glaucoma Reimbursement Landscape Nov 20
IRIDEX Corporation Announces Board and Committee Changes Nov 16
IRIDEX Corporation to Report Q3, 2024 Results on Nov 12, 2024 Nov 05 Iridex Corporation Announces Chief Executive Officer Changes IRIDEX Corporation announced that it expects to receive $5 million in funding from The Lind Partners, LLC Aug 06
IRIDEX Corporation announced that it expects to receive $5 million in funding from The Lind Partners, LLC Aug 05
IRIDEX Corporation to Report Q2, 2024 Results on Aug 08, 2024 Jul 31
IRIDEX Begins the Process to Transfer the Listing of its Common Stock from The Nasdaq Global Market to The Nasdaq Capital Market Jul 05 IRIDEX Begins the Process to Transfer the Listing of its Common Stock from The Nasdaq Global Market to The Nasdaq Capital Market Jul 04
IRIDEX Corporation Announces Composition of Audit Committee Jun 21
Revenues Working Against IRIDEX Corporation's (NASDAQ:IRIX) Share Price Following 26% Dive Jun 11
IRIDEX Corporation Appoints Patrick Mercer as Its President May 25
Consensus EPS estimates fall by 32% May 21
First quarter 2024 earnings: EPS and revenues miss analyst expectations May 16
Is IRIDEX (NASDAQ:IRIX) In A Good Position To Invest In Growth? May 14
IRIDEX Corporation to Report Q1, 2024 Results on May 14, 2024 May 10
IRIDEX Corporation, Annual General Meeting, Jun 18, 2024 May 01
Iridex's Strategic Review Process Should Bear Fruit 'Soon' Mar 28
Full year 2023 earnings: EPS and revenues miss analyst expectations Mar 28
IRIDEX Corporation to Report Q4, 2023 Results on Mar 26, 2024 Mar 21
Little Excitement Around IRIDEX Corporation's (NASDAQ:IRIX) Revenues Feb 14
Price target decreased by 48% to US$2.00 Feb 14
Iridex Corporation Announces First Patient Enrollment in MicroPulse® TLT Clinical Study Conducted in Collaboration with Imperial College Healthcare NHS Trust Jan 25
Iridex Corporation Launches New Iridex 532 and Iridex 577 Lasers in US Market Marking 35 Years of Laser Innovation in Treating Retina Disorders & Glaucoma Jan 12
Iridex Corporation Announces Successful Appeal for Revision of Recent Medicare LCDs to Provide Broader Coverage of Cyclophotocoagulation Nov 29
Iridex Corporation Announces Successful Appeal for Revision of Recent Medicare LCDs to Provide Broader Coverage of Cyclophotocoagulation Nov 28
IRIDEX Corporation announced delayed 10-Q filing Nov 16 IRIDEX Corporation announced delayed 10-Q filing
New major risk - Share price stability Nov 02
IRIDEX Corporation to Report Q3, 2023 Results on Nov 14, 2023 Oct 27
Will IRIDEX (NASDAQ:IRIX) Spend Its Cash Wisely? Oct 04
Consensus EPS estimates fall by 35% Aug 17
New minor risk - Share price stability Aug 14
Lacklustre Performance Is Driving IRIDEX Corporation's (NASDAQ:IRIX) 32% Price Drop Aug 12
Second quarter 2023 earnings: EPS and revenues miss analyst expectations Aug 11
IRIDEX Corporation Provides Revenue Guidance for the Year 2023 Aug 11
IRIDEX Corporation to Report Q2, 2023 Results on Aug 10, 2023 Jul 29
First quarter 2023 earnings: EPS misses analyst expectations May 13
IRIDEX Corporation Reiterates Financial Guidance for 2023 May 12
Will IRIDEX (NASDAQ:IRIX) Spend Its Cash Wisely? Apr 14
Consensus EPS estimates fall by 13% Mar 16
Full year 2022 earnings: EPS exceeds analyst expectations Mar 11
IRIDEX Corporation Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022 Jan 11
Price target decreased to US$5.63 Nov 16
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Nov 12
IRIDEX Corporation Provides Revenue Guidance for the Year 2022 Nov 11
IRIDEX Corporation to Report Q3, 2022 Results on Nov 10, 2022 Oct 28
We're Hopeful That IRIDEX (NASDAQ:IRIX) Will Use Its Cash Wisely Oct 12
Iridex Corporation Showcases its Non-Incisional Treatments for Glaucoma and Introduces Sweep Management Software at AAO 2022 Sep 30
IRIDEX Corporation Revises Revenue Guidance for the Full Year 2022 Aug 17
Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Aug 16
IRIDEX Corporation to Report Q2, 2022 Results on Aug 15, 2022 Aug 02
IRIDEX Corporation Obtains Regulatory Clearance for Cyclo G6(R) Glaucoma Platform in China Jun 15
IRIDEX Corporation Provides Revenue Guidance for the Full Year 2022 May 14
First quarter 2022 earnings: EPS exceeds analyst expectations May 13
Price target increased to US$9.75 Apr 27
Iridex Corporation Modifies the Composition of its Audit Committee, Compensation Committee, and Nominating and Governance Committee Apr 22
Consensus EPS estimates fall by 62% Mar 17
Full year 2021 earnings: EPS and revenues exceed analyst expectations Mar 12
IRIDEX Corporation to Report Q4, 2021 Results on Mar 10, 2022 Feb 25
Third quarter 2021 earnings released: US$0.14 loss per share (vs US$0.12 loss in 3Q 2020) Nov 13
Second quarter 2021 earnings released: EPS US$0.089 (vs US$0.20 loss in 2Q 2020) Aug 14
Iridex Corporation Revises Earnings Guidance for the Year 2021 Aug 13
No longer forecast to breakeven Jun 23
Price target increased to US$10.50 Jun 23
IRIDEX Corporation Provides Earnings Guidance for the Fiscal Year 2021 May 12
Iridex Corporation Announces It Cannot Provide Meaningful Financial Guidance for 2021 Mar 23 IRIDEX Corporation announced that it has received $10 million in funding from Topcon America Corporation
IRIDEX Corporation to Report Q4, 2020 Results on Mar 22, 2021 Mar 09
IRIDEX Corporation (NasdaqGM:IRIX) entered into an asset purchase agreement to acquire substantially all the assets from Topcon Medical Laser Systems Inc. Mar 04
Is IRIDEX (NASDAQ:IRIX) Using Too Much Debt? Feb 25
New 90-day high: US$5.82 Feb 17
Price target raised to US$6.50 Jan 23
New 90-day high: US$4.13 Jan 13
Iridex To Benefit From New Revolutionary Glaucoma Treatment Jan 11
Analysts Expect Breakeven For IRIDEX Corporation (NASDAQ:IRIX) Before Long Jan 03
IRIDEX says laser therapy now accepted in the European Glaucoma Society guidelines Dec 23
New 90-day low: US$1.66 Dec 17
New 90-day low: US$1.67 Nov 20
Third quarter 2020 earnings released: US$0.12 loss per share Nov 11
Revenue beats expectations, earnings disappoint Nov 11
IRIDEX Corporation Announces Change of Interim CFO Nov 10
New 90-day low: US$1.76 Nov 03
IRIDEX Corporation to Report Q3, 2020 Results on Nov 09, 2020 Oct 28
New 90-day low - US$1.91 Sep 09
Earnings released Aug 07 Shareholder Returns IRIX US Medical Equipment US Market 7D -4.7% -1.5% -2.4% 1Y -36.8% 10.1% 23.3%
See full shareholder returns
Return vs Market: IRIX underperformed the US Market which returned 23.3% over the past year.
Price Volatility Is IRIX's price volatile compared to industry and market? IRIX volatility IRIX Average Weekly Movement 11.9% Medical Equipment Industry Average Movement 7.6% Market Average Movement 6.3% 10% most volatile stocks in US Market 16.8% 10% least volatile stocks in US Market 3.1%
Stable Share Price: IRIX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: IRIX's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders.
Show more IRIDEX Corporation Fundamentals Summary How do IRIDEX's earnings and revenue compare to its market cap? IRIX fundamental statistics Market cap US$27.28m Earnings (TTM ) -US$11.04m Revenue (TTM ) US$48.43m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) IRIX income statement (TTM ) Revenue US$48.43m Cost of Revenue US$29.63m Gross Profit US$18.80m Other Expenses US$29.84m Earnings -US$11.04m
Last Reported Earnings
Sep 28, 2024
Earnings per share (EPS) -0.66 Gross Margin 38.82% Net Profit Margin -22.79% Debt/Equity Ratio 105.1%
How did IRIX perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 03:54 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/28 Annual Earnings 2023/12/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources IRIDEX Corporation is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Scott Henry Roth MKM Joseph Munda Sidoti & Company, LLC Lisa Springer Singular Research
Show 1 more analysts 
